A randomized, open label, balanced, two-treatment, two-period, two-sequence, crossover, bioequivalence study of Single dose (0.6 mg) of Liraglutide 6 mg/ml solution for injection in pre-filled pen of Biocon Pharma Limited, India with Single dose (0.6 mg) of Victoza® (Liraglutide) 6 mg/ml solution for injection in pre-filled pen of Novo Nordisk A/S, Denmark, administered subcutaneously in healthy adult human subjects, under fasting condition - LIRA VICTOZA BE
A randomized open label two treatment two period two sequence crossover comparative bioavailability study of Single dose (0.6 mg) of Liraglutide 6 mg/ml solution for injection in pre-filled pen of Biocon Pharma Limited India with Single dose (0.6 mg) of Victoza�® (liraglutide) 6 mg/ml solution for injection in pre-filled pen of Novo Nordisk A/S Denmark administered subcutaneously in healthy adult human subjects under fasting condition - LIRAPK
A randomized, open label, balanced, two-treatment, two-period, two-sequence, crossover,bioequivalence study of Single dose (0.6 mg) of Liraglutide 6 mg/ml solution for injectionin pre-filled pen of Biocon Pharma Limited, India with Single dose (0.6 mg) of Saxenda®(Liraglutide) 6 mg/ml solution for injection in pre-filled pen of Novo Nordisk A/S,Denmark, administered subcutaneously in healthy adult human subjects, under fastingcondition
100 Clinical Results associated with Biocon Pharma Ltd.
0 Patents (Medical) associated with Biocon Pharma Ltd.
100 Deals associated with Biocon Pharma Ltd.
100 Translational Medicine associated with Biocon Pharma Ltd.